文献速递神经肌肉病认知障碍与痴呆

UNC13A基因多态性在肌萎缩侧索硬化中的独特特征

The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral Sclerosis.
PubMed 文献 · Ann Neurol · 2020-07-20

本研究纳入2216例无C9orf72突变的ALS患者,分析UNC13A rs12608932多态性与临床、认知、行为及神经影像表型的关联。C等位基因与更高的发病年龄、延髓起病、ALS-FTD、较低用力肺活量、较短生存期、较差认知评分及更多行为异常相关,并伴特定脑皮质变薄。

要点

  • UNC13A C等位基因携带者发病年龄更高、延髓起病更常见。
  • C等位基因与ALS-FTD发生率更高、诊断时用力肺活量更低相关。
  • C等位基因携带者生存期更短、认知评分更低、行为异常更频繁。

核心结论

  • UNC13A rs12608932多态性相关的表型差异应纳入临床试验设计、认知行为研究和预后咨询的考量。

研究设计与样本

  • 纳入2216例无C9orf72突变的ALS患者分析临床特征,其中428例研究认知行为,375例研究神经影像,采用加性遗传模型。

主要发现

  • C等位基因与更高的发病年龄相关(中位年龄A/A 63.5岁,A/C 65.6岁,C/C 65.5岁;p<0.001)。
  • C等位基因与更频繁的延髓起病相关(A/A 29.6%,A/C 31.8%,C/C 43.1%;p<0.001)。
  • C等位基因与更高的ALS-FTD发生率相关(A/A 4.3%,A/C 5.2%,C/C 9.5%;p=0.003)。
  • C等位基因与诊断时更低的用力肺活量相关(中位百分比A/A 92.0,A/C 90.0,C/C 86.5;p<0.001)。
  • C等位基因与更短的生存期相关(中位月数A/A 33.3,A/C 30.7,C/C 26.6;p<0.001)。

关键数值与推荐

  • UNC13A与ALS特异性认知测试较低评分相关(均值A/A 79.5,A/C 78.1,C/C 76.6;p=0.037)。
  • UNC13A与更频繁的行为异常相关(A/A 16.7%,A/C 24.4%,C/C 27.7%;p=0.045)。
  • 左侧颞下回和右侧梭状回皮质变薄与UNC13A单核苷酸多态性相关(p=0.045和p=0.036)。

临床怎么用

  • 对ALS患者进行UNC13A基因分型有助于预后咨询,C等位基因携带者可能预后更差。
  • 在临床试验设计中应考虑UNC13A基因型对治疗反应和表型的影响。

局限性

  • 研究未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The rs12608932 single nucleotide polymorphism in UNC13A is associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) susceptibility, and may underlie differences in treatment response. We aimed to characterize the clinical, cognitive, behavioral, and neuroimaging phenotype of UNC13A in patients with ALS. METHODS: We included 2,216 patients with ALS without a C9orf72 mutation to identify clinical characteristics associated with the UNC13A polymorphism. A subcohort of 428 patients with ALS was used to study cognitive and behavioral profiles, and 375 patients to study neuroimaging characteristics. Associations were analyzed under an additive genetic model. RESULTS: Genotyping rs12608932 resulted in 854 A/A, 988 A/C, and 374 C/C genotypes. The C allele was associated with a higher age at symptom onset (median years A/A 63.5, A/C 65.6, and C/C 65.5; p < 0.001), more frequent bulbar onset (A/A 29.6%, A/C 31.8%, and C/C 43.1%; p < 0.001), higher incidences of ALS-FTD (A/A 4.3%, A/C 5.2%, and C/C 9.5%; p = 0.003), lower forced vital capacity at diagnosis (median percentage A/A 92.0, A/C 90.0, and C/C 86.5; p < 0.001), and a shorter survival (median in months A/A 33.3, A.C 30.7, and C/C 26.6; p < 0.001). UNC13A was associated with lower scores on ALS-specific cognition tests (means A/A 79.5, A/C 78.1, and C/C 76.6; p = 0.037), and more frequent behavioral disturbances (A/A 16.7%, A/C 24.4%, and C/C 27.7%; p = 0.045). Thinner left inferior temporal and right fusiform cortex were associated with the UNC13A single nucleotide polymorphism (SNP; p = 0.045 and p = 0.036). INTERPRETATION: Phenotypical distinctions associated with UNC13A make it an important factor to take into account in clinical trial design, studies on cognition and behavior, and prognostic counseling. ANN NEUROL 2020;88:796-806.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Tan HHG, Westeneng HJ, van der Burgh HK, et al. The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral Sclerosis. Ann Neurol. 2020. PMID: 32627229. doi:10.1002/ana.25841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。